Center for Scientific Review; Notice of Closed Meetings, 19211-19212 [2016-07483]
Download as PDF
Federal Register / Vol. 81, No. 64 / Monday, April 4, 2016 / Notices
Dated: March 29, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–07484 Filed 4–1–16; 8:45 am]
BILLING CODE 4140–01–P
Rose Freel, Ph.D., Licensing and
Patenting Manager, Technology Transfer
Center, National Cancer Institute, 8490
Progress Drive, Riverside 5, Suite 400,
Frederick, MD 21702; Telephone: (301)
624–1257; Email: rose.freel@nih.gov.
5T4 is an
antigen expressed on many different
types of cancers, especially solid
tumors. Its expression is limited in
normal tissue, but is prevalent in
malignant tumors throughout their
development making it an attractive
target for cancer immunotherapy. 5T4 is
often found in colorectal, ovarian, and
gastric tumors and as a result, has been
used as a prognostic aid for these
cancers. The role of 5T4 in antibodydirected immunotherapy has been
studied using murine monoclonal
antibodies (mAbs). In addition, the
cancer vaccine TroVax (currently in
clinical trials for multiple solid tumors)
targets 5T4. The present invention
describes the identification and
characterization of two fully human
mAbs (m1001 and m1002) that bind to
5T4. Since the mAbs are fully human,
they could have less immunogenicity
and better safety profiles than the
existing mouse and humanized
antibodies. These mAbs have the
potential to be cancer therapeutics as
naked mAbs, chimeric antigen receptors
(CARs) or antibody-drug conjugates
(ADCs).
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR part 404.7. The
prospective exclusive license may be
granted unless within fifteen (15) days
from the date of this published notice,
the National Cancer Institute receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
19211
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Development of 5T4
Antibodies in Human Cancer
Therapeutics and Diagnostics
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Cancer Institute,
National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an exclusive patent license to practice
the inventions embodied in the
following U.S. Patents and Patent
Applications to Ovensa, Inc. (‘‘Ovensa’’)
located in Ontario, Canada.
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
Intellectual Property
U.S. Provisional Patent Application
No. 62/034,995 filed August 8, 2014
entitled ‘‘Human Monoclonal
Antibodies Specific for 5T4 and
Methods of Their Use’’ [HHS Ref. No. E–
158–2014/0–US–01];
PCT Application No. PCT/US2015/
044253 filed August 8, 2015 entitled
‘‘Human Monoclonal Antibodies
Specific for 5T4 and Methods of Their
Use’’ [HHS Ref. No. E–158–2014/0–
PCT–02].
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to ‘‘the use
of the Licensed Patent Rights in
combination with the Licensee’s
proprietary or exclusively in-licensed
platforms and technologies for the
treatment, prevention or diagnosis of
cancer.’’
DATES: Only written comments and/or
applications for a license which are
received by the Technology Transfer
Center at the National Cancer Institute
on or before April 19, 2016 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
exclusive license should be directed to:
VerDate Sep<11>2014
19:03 Apr 01, 2016
Jkt 238001
Dated: March 29, 2016.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2016–07556 Filed 4–1–16; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00100
Fmt 4703
Sfmt 4703
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; AIDS and
Related Research NAED Conflicts.
Date: April 5, 2016.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Robert Freund, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5216,
MSC 7852, Bethesda, MD 20892, 301–435–
1050, freundr@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR16–028:
HIV/AIDS Vaccine Scholars Program.
Date: April 7, 2016.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Barna Dey, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3184,
Bethesda, MD 20892, 301–451–2796, bdey@
mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Multidisciplinary Studies on HIV and Aging.
Date: April 8, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\04APN1.SGM
04APN1
19212
Federal Register / Vol. 81, No. 64 / Monday, April 4, 2016 / Notices
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Shiv A. Prasad, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5220,
MSC 7852, Bethesda, MD 20892, 301–443–
5779, prasads@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: March 29, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–07483 Filed 4–1–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Institute on
Aging Special Emphasis Panel, May 09,
2016, 12:00 p.m. to May 09, 2016, 04:00
p.m., National Institute on Aging,
Gateway Building, 7201 Wisconsin
Ave., 2C212, Bethesda, MD 20892
which was published in the Federal
Register on March 25, 2016, 81FR16189.
The meeting notice is amended to
change the time of the meeting on May
9, 2016 from 12:00 p.m. to 4:00 p.m. to
the new time of 9:30 a.m. to 1:30 p.m.
The meeting is closed to the public.
Dated: March 28, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–07500 Filed 4–1–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
mstockstill on DSK4VPTVN1PROD with NOTICES
National Institutes of Health
National Institute on Deafness and
Other Communication Disorders;
Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Deafness and Other
VerDate Sep<11>2014
19:03 Apr 01, 2016
Jkt 238001
Communication Disorders Advisory
Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Deafness and
Other Communication Disorders Advisory
Council.
Date: May 20, 2016.
Closed: 8:30 a.m. to 9:40 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, Room 6, 31 Center Drive,
Bethesda, MD 20892.
Open: 9:40 a.m. to 2:00 p.m.
Agenda: Staff reports on divisional,
programmatic, and special activities
Place: National Institutes of Health,
Building 31, Room 6, 31 Center Drive,
Bethesda, MD 20892.
Contact Person: Craig A. Jordan, Ph.D.,
Director, Division of Extramural Activities
NIDCD, NIH, Room 8345, MSC 9670, 6001
Executive Blvd., Bethesda, MD 20892–9670,
301–496–8693, jordanc@nidcd.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.nidcd.nih.gov/about/Pages/AdvisoryGroups-and-Review-Committees.aspx, where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.173, Biological Research
PO 00000
Frm 00101
Fmt 4703
Sfmt 9990
Related to Deafness and Communicative
Disorders, National Institutes of Health, HHS)
Dated: March 24, 2016.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–07479 Filed 4–1–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Myalgic
Encephalomyelitis/Chronic Fatigue
Syndrome.
Date: April 5, 2016.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: M. Catherine Bennett,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5182,
MSC 7846, Bethesda, MD 20892, 301–435–
1766, bennettc3@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: March 29, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–07485 Filed 4–1–16; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\04APN1.SGM
04APN1
Agencies
[Federal Register Volume 81, Number 64 (Monday, April 4, 2016)]
[Notices]
[Pages 19211-19212]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-07483]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; AIDS and Related Research NAED Conflicts.
Date: April 5, 2016.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Robert Freund, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 5216, MSC 7852, Bethesda, MD 20892, 301-435-
1050, freundr@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR16-028: HIV/AIDS Vaccine Scholars Program.
Date: April 7, 2016.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Barna Dey, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3184, Bethesda, MD 20892, 301-451-2796,
bdey@mail.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR Panel: Multidisciplinary Studies on HIV and Aging.
Date: April 8, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
[[Page 19212]]
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892.
Contact Person: Shiv A. Prasad, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5220, MSC 7852, Bethesda, MD
20892, 301-443-5779, prasads@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: March 29, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-07483 Filed 4-1-16; 8:45 am]
BILLING CODE 4140-01-P